Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sterile saline injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

NCT04845178
View directory record Official record
Conditions
Migraine
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

NCT06413095
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 9, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638
View directory record Official record
Conditions
Extreme Immaturity
Interventions
Sodium chloride, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days to 8 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)

NCT02105558
View directory record Official record
Conditions
Labor Pain, Complications; Cesarean Section, Pregnancy
Interventions
Epidural anesthesia, Combined spinal and epidural anesthesia
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03397121
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

NCT04240535
View directory record Official record
Conditions
Aging
Interventions
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Drug
Lead sponsor
Amir Moradi MD, MBA
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

NCT00924963
View directory record Official record
Conditions
Pain
Interventions
J-Tip jet injector, Jet injection saline, lidocaine cream
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Liberty Township, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blossom® Smart Expander Device for Tissue Expander/Implant-Based Breast Reconstruction

NCT05975372
View directory record Official record
Conditions
Tissue Expansion, Implant Based Breast Reconstruction
Interventions
Blossom tissue expander, Standard tissue expansion
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

NCT03406611
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet-rich Plasma for Eyebrows

NCT04018859
View directory record Official record
Conditions
Eyebrow Hypotrichosis
Interventions
Platelet Rich Plasma Prep System, Saline
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Not listed Not applicable Interventional

Effectiveness for Interventions to Minimize Surgical Site Infections

NCT01153191
View directory record Official record
Conditions
Infections
Interventions
Normal saline pressurized irrigation, sub-q gentamicin
Procedure · Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 95 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

NCT06390956
View directory record Official record
Conditions
Marginal Zone Lymphoma
Interventions
Pirtobrutinib, Rituximab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 4 Interventional

Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty

NCT06384651
View directory record Official record
Conditions
Infections, Ankle Arthritis
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

NCT01074229
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 9, 2026, 1:46 PM EDT